TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15338504

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg qd
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg qd
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Ibuprofen 800 mg tid
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Celecoxib 200 mg qd
Number of subjects: 1042
Study: 11575411

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 24
Study: 9645980

Group type: EXPERIMENTAL
Intervention: Carotid balloon angioplasty
Number of subjects: 29
Study: 8294693

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5025

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5025
Study: 2738720

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) 750 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29271278

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU of oral vitamin D3 once weekly)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27593544

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Ecologic Barrier, Winclove, Amsterdam, The Netherlands) daily for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24753491

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 12 months
Number of subjects: 507

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 507
Study: 23425142

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment and chlorhexidine body wash (treated carriers)
Number of subjects: 738

Group type: COMPARATOR
Intervention: No treatment (untreated carriers)
Number of subjects: 738

Group type: COMPARATOR
Intervention: No treatment (non-carriers)
Number of subjects: 738
Study: 20015040

Group type: EXPERIMENTAL
Intervention: 11β-HSD1 selective inhibitors (e.g., DIO-902, INCB13739)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel chemicals that inhibit 11β-HSD1 reductase and increase oxidase activity
Number of subjects: 0
Study: 19100003

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus Hydrochlorothiazide 12.5 mg (TH)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Telmisartan 80 mg (T)
Number of subjects: 345
Study: 15723265

Group type: EXPERIMENTAL
Intervention: Aspirin (acetylsalicylic acid, ASA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-diabetic subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 0
Study: 11853119

Group type: EXPERIMENTAL
Intervention: bromperidol (6, 12 or 18 mg/day) for 3 weeks
Number of subjects: 30
Study: 10486474

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 189

Group type: COMPARATOR
Intervention: Intravaginal dinoprostone
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol and dinoprostone
Number of subjects: 189
Study: 8671503

Group type: EXPERIMENTAL
Intervention: 2500 IU HCG (HCG+ group)
Number of subjects: 170

Group type: COMPARATOR
Intervention: No HCG (HCG‐ group)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: HCG+ group
Number of subjects: 170

Group type: COMPARATOR
Intervention: HCG‐ group
Number of subjects: 170
Study: 1754671

Group type: EXPERIMENTAL
Intervention: Food elimination diet
Number of subjects: 91

Group type: COMPARATOR
Intervention: Food challenges
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Initial serum IgG levels
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Radioallergosorbent test to soy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Serum or complexed immunoglobulins
Number of subjects: 91

Group type: COMPARATOR
Intervention: Initial serum immunoglobulin levels
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: History of spring/summer exacerbations of eczema
Number of subjects: 91
Study: 30039387

Group type: EXPERIMENTAL
Intervention: Cranberry tablets alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cranberry tablets containing vitamin C
Number of subjects: 15
Study: 28832310

Group type: EXPERIMENTAL
Intervention: DA + SDM
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: DA
Number of subjects: 329

Group type: COMPARATOR
Intervention: UC
Number of subjects: 329
Study: 25243647

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 25010824

Group type: EXPERIMENTAL
Intervention: Physical therapy combined with pulsed radiofrequency (PRF) lesioning of the suprascapular nerve (SSN) for 12 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical therapy alone for 12 weeks.
Number of subjects: 60
Study: 21831230

Group type: EXPERIMENTAL
Intervention: Clove and lemon balm extract
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clove and agrimony extract
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 120
Study: 19774311

Group type: EXPERIMENTAL
Intervention: Qigong intervention (twice a week for 12 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Basic care
Number of subjects: 82
Study: 17572792

Group type: EXPERIMENTAL
Intervention: Life skills education (26-hour competence promotion for students and 5-hour parent training)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Internal control group
Number of subjects: 208

Group type: COMPARATOR
Intervention: External control group
Number of subjects: 208
Study: 16391401

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) for 3 months in SPS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) for 3 months in DM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 3 months in SPS
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 3 months in DM
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) for 3 months in IBM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 3 months in IBM
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in SPS
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) in DM
Number of subjects: 50
Study: 12428313

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside infusion to maintain controlled hypotension with MAP around 60 mmHg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mean arterial blood pressure (MAP) maintained around 80 mmHg (Control Group C)
Number of subjects: 0
Study: 9709937

Group type: COMPARATOR
Intervention: Active/Placebo patch (AP group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Active/Active patch (AA group)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo patch (PP group)
Number of subjects: 53
Study: 8561689

Group type: EXPERIMENTAL
Intervention: Subjects with OM histories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls (no OM histories)
Number of subjects: 0
Study: 2242951

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (10 capsules, three times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil capsules (10 capsules, three times daily)
Number of subjects: 0
Study: 45195

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Orciprenaline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29781315

Group type: EXPERIMENTAL
Intervention: Topical antibiotic treatment for Staphylococcus aureus (SA) colonization
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional germiculture method
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Topical antibiotic treatment
Number of subjects: 80
Study: 30017459

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) with longitudinal formulation in the first 4 sessions
Number of subjects: 0
Study: 27589523

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 7 mg/month
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 2 mg/month
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 20 mg/month
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 24449631

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 44
Study: 22086119

Group type: EXPERIMENTAL
Intervention: Intrasomatic injections of 4 mg/ml of dexamethasone phosphate followed by vertebroplasty
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vertebroplasty alone
Number of subjects: 20
Study: 19237497

Group type: EXPERIMENTAL
Intervention: High threat and high coping information
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Threat appraisal information
Number of subjects: 254
Study: 17495819

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 50
Study: 15496046

Group type: EXPERIMENTAL
Intervention: Zinc (administered within 24 hours of onset of symptoms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (administered as a nasal gel)
Number of subjects: 0
Study: 11170188

Group type: EXPERIMENTAL
Intervention: Method 1: Instructed to try to inhibit micturition during bladder filling
Number of subjects: 42

Group type: COMPARATOR
Intervention: Method 2: Instructed to neither try to void nor inhibit micturition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Method 1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Method 2
Number of subjects: 42
Study: 9554395

Group type: EXPERIMENTAL
Intervention: F-15 scan (furosemide injected 15 minutes before renography)
Number of subjects: 72

Group type: COMPARATOR
Intervention: F+20 scan (furosemide injected 20 minutes after radiopharmaceutical)
Number of subjects: 72
Study: 8276366

Group type: EXPERIMENTAL
Intervention: Flumazenil (2 mg, intravenous)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (20 ml solution, intravenous)
Number of subjects: 21
Study: 2657048

Group type: EXPERIMENTAL
Intervention: salsalate (3 g/day, adjusted for efficacy and tolerance)
Number of subjects: 233

Group type: COMPARATOR
Intervention: aspirin (3.6 g/day, adjusted for efficacy and tolerance)
Number of subjects: 233
Study: 4613978

Group type: EXPERIMENTAL
Intervention: Dapsone, 100 mg daily for 14 consecutive days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo capsule for the remaining 56 days
Number of subjects: 17
Study: 31072196

Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 22

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 22
Study: 28554928

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA) with patient-controlled epidural administration of ropivacaine and sufentanil combined with standard care
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 148
Study: 26715476

Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine solution applied twice daily after usual oral hygiene care
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group with no application after usual oral hygiene care
Number of subjects: 500
Study: 23137657

Group type: EXPERIMENTAL
Intervention: LightCycler® SeptiFast (LC‐SF) assay
Number of subjects: 35

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 35
Study: 21190403

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive-behavioral therapy (CBT)
Number of subjects: 77
Study: 18647291

Group type: EXPERIMENTAL
Intervention: Direct technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rotational technique
Number of subjects: 100
Study: 16497822

Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 813
Study: 12643970

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 80
Study: 17077660

Group type: EXPERIMENTAL
Intervention: 0.35% fluorexon disodium and 0.4% benoxinate
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.25% sodium fluorescein and 0.4% benoxinate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 0.35% fluorexon disodium
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.25% sodium fluorescein
Number of subjects: 67
Study: 10231452

Group type: EXPERIMENTAL
Intervention: Dialysate iron group (ferric pyrophosphate via hemodialysis at 12 micrograms/dl)
Number of subjects: 21

Group type: COMPARATOR
Intervention: i.v. iron group (iron dextran)
Number of subjects: 21

Group type: COMPARATOR
Intervention: i.v. iron group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dialysate iron group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 8569362

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (35.0 [0.5] degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normothermia (36.6 [0.4] degrees C)
Number of subjects: 60
Study: 1945464

Group type: EXPERIMENTAL
Intervention: Hylak forte
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7266633

Group type: EXPERIMENTAL
Intervention: Various antibiotic regimens
Number of subjects: 26

Group type: COMPARATOR
Intervention: No antibiotic treatment (Control)
Number of subjects: 26
Study: 31030865

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Framingham Risk Score (FRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27557042

Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vacuum-formed retainer
Number of subjects: 20
Study: 25683972

Group type: EXPERIMENTAL
Intervention: i.v. ferric carboxymaltose (FCM)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 24451151

Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Daclatasvir 10 mg and 60 mg
Number of subjects: 42
Study: 23112909

Group type: EXPERIMENTAL
Intervention: Topical application of cholecalciferol (vitamin D(3)) for 3 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 83
Study: 18829143

Group type: EXPERIMENTAL
Intervention: Nurses taught by nurse-instructors (Group A)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Nurses taught by doctor-instructors (Group B)
Number of subjects: 108
Study: 17511788

Group type: EXPERIMENTAL
Intervention: Thermafil system (TF group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Step-back technique and lateral condensation (LC group)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Super Ethoxybenzoic Acid (sEBA)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Intermediate Restorative Material (IRM)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Negative controls (n = 12)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Positive controls (n = 8)
Number of subjects: 92
Study: 15304127

Group type: EXPERIMENTAL
Intervention: Angiography group (n = 34) received additional angiography 1 month after achievement of CN.
Number of subjects: 68

Group type: COMPARATOR
Intervention: CT group (n = 34) followed using dynamic CT every 3 months without any further intervention.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Angiography group (n = 34)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CT group (n = 34)
Number of subjects: 68
Study: 11371741

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.05 mg/kg per day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 9564120

Group type: EXPERIMENTAL
Intervention: Long-acting opioid medications
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 29
Study: 8034823

Group type: EXPERIMENTAL
Intervention: Commitment-based intervention (verbal and written commitments for adherence, tasks to increase investment in medication regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (performed tasks unrelated to the medical regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 0
Study: 28297591

Group type: EXPERIMENTAL
Intervention: Estrogen replacement (oral 30 µg ethinyl estradiol or transdermal 100 µg 17‐β‐estradiol patch)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No estrogen (control group)
Number of subjects: 48
Study: 25926416

Group type: EXPERIMENTAL
Intervention: DHA (400 mg/d)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study: 24073532

Group type: EXPERIMENTAL
Intervention: Silorane-based group (Filtek P90/Silorane System Adhesive - 3M ESPE)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Methacrylate-based group (Filtek P60/Adper SE Plus - 3M ESPE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 33
Study: 21612677

Group type: EXPERIMENTAL
Intervention: 1-piece SA60AT IOL
Number of subjects: 51

Group type: COMPARATOR
Intervention: 3-piece MA60BM IOL
Number of subjects: 51
Study: 18155501

Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Charged coupled device (CCD)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Photostimulable phosphor plate (PSP)
Number of subjects: 72
Study: 17211116

Group type: EXPERIMENTAL
Intervention: Structured drug education program
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study: 12975729

Group type: EXPERIMENTAL
Intervention: Semitendinosus and gracilis tendon autografts (ST/G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Central third of the patella tendon (BPT)
Number of subjects: 40
Study: 10876329

Group type: EXPERIMENTAL
Intervention: Center for Epidemiologic Studies‐‐Depression Scale (CES-D)
Number of subjects: 80
Study: 9360096

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control grafts
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (Phase II)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (overall 7 year follow-up)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (fibronectin treated)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Endothelialized grafts (above-knee group, fibronectin treated)
Number of subjects: 108
Study: 8472827

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal pressure support ventilation (NPSV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control night without ventilation
Number of subjects: 12
Study: 3513567

Group type: EXPERIMENTAL
Intervention: 10 mg folic acid per day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 28791887

Group type: EXPERIMENTAL
Intervention: Burdensome condition
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Burdensome condition with AS physical concerns
Number of subjects: 262
Study: 27013640

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus metronidazole (MTZ) 400 mg TID and amoxicillin (AMX) 500 mg TID for 14 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus metronidazole (MTZ) and amoxicillin (AMX)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MTZ + AMX intake
Number of subjects: 58
Study: 25012289

Group type: EXPERIMENTAL
Intervention: ISIS 329993 (ISIS‐CRPR x) at 400 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ISIS 329993 (ISIS‐CRPR x) at 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22449293

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily)
Number of subjects: 4832

Group type: COMPARATOR
Intervention: Standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months
Number of subjects: 4832

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 4832

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 4832
Study: 21104507

Group type: EXPERIMENTAL
Intervention: AlcoholEdu for College 8.0 (online alcohol course)
Number of subjects: 1620

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 1620
Study: 18455592

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 50

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cardiac troponin I
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heart-type fatty acid-binding protein
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increased cardiac troponin I levels (>0.92 ng/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increased heart-type fatty acid-binding protein levels (>6.8 ng/mL)
Number of subjects: 50
Study: 15994267

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (FP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Inhaled steroids (FP)
Number of subjects: 31
Study: 12363064

Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60